Haloperidol Galvany Pharma (Haloperidol)

Haloperidol Galvany Pharma injection is indicated for the management of several acute psychiatric conditions.

• Schizophrenia, particularly when rapid control of symptoms is required.
• Acute psychotic episodes, including those associated with substance use or medical illness.
• Manic episodes of bipolar disorder presenting with severe agitation.
• Severe agitation or hostility that poses a risk to the patient or others.
• Adjunctive treatment during emergency stabilization of patients with known psychotic disorders.
• Pre‑operative sedation in patients with psychotic symptoms requiring surgical procedures.

Side effects of haloperidol injection can vary in frequency and severity; they are categorized as common or serious.

Common

• Drowsiness or sedation, often most noticeable after the first injection.
• Mild extrapyramidal symptoms such as tremor, rigidity, or muscle stiffness.
• Dry mouth and reduced salivation, leading to a sensation of thirst.
• Constipation or slowed gastrointestinal motility.

Serious

• Neuroleptic malignant syndrome, a rare but life‑threatening reaction with fever and muscle rigidity.
• Tardive dyskinesia, potentially irreversible involuntary movements after prolonged exposure.
• Cardiac arrhythmias, including QT‑interval prolongation that may increase risk of torsades de pointes.

When prescribing haloperidol injection, clinicians should consider several precautions to minimize risks and ensure appropriate use.

• Assess cardiovascular status, as haloperidol may cause hypotension or QT prolongation.
• Evaluate for a history of movement disorders, including Parkinson’s disease or prior extrapyramidal reactions.
• Use the lowest effective dose for the shortest duration needed to control symptoms.
• Monitor for signs of neuroleptic malignant syndrome, especially during the first few days of therapy.
• Caution in patients with hepatic or renal impairment, adjusting dose as clinically indicated.
• Avoid use in individuals with known hypersensitivity to haloperidol or other butyrophenones.

Haloperidol can interact with other medications; some combinations should be avoided while others require careful monitoring.

Avoid

• Concurrent use with other dopamine antagonists or high‑potency antipsychotics, which may increase extrapyramidal risk.
• Co‑administration with drugs that markedly prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.

Use with caution

• CNS depressants (e.g., benzodiazepines, opioids) may enhance sedation and respiratory depression.
• Anticholinergic agents can mask early signs of extrapyramidal symptoms.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may raise haloperidol plasma levels.
• CYP3A4 inducers (e.g., carbamazepine, rifampin) may reduce therapeutic effectiveness.